Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery. Lalit Kumar is an Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research, Hajipur, Vaishali, Bihar, India. His area of research includes the development of nanocarriers for drug-targeting tumor cells in the colon, brain, breast, and lungs. Dr. Dalapathi Gugulothu working as Assistant professor, Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University , New Delhi.

• I. Biomarkers in Cancer Diagnosis and Treatment1. Prostate-Specific Antigen (PSA)2. Carcinoembryonic Antigen (CEA)3. Tissue Polypeptide-Specific Antigen (TPS) CA72-44. Carbohydrate Antigen 19-9 (CA19-9)5. Carbohydrate Antigen 125 (CA-125)6. Carbohydrate Antigen 72-4 (CA72-4)7. Aminopeptidase N8. Alkaline Phosphatase9. CD26/Dipeptidyl Peptidase (DPP)410. Genetic Biomarkers in Cancer11. Immunology Biomarkers in Cancer12. Microbiome Biomarkers in Cancer13. Glycobiology Biomarkers in Cancer14. Epigenetic Biomarkers in CancerII. Metabolic Targets and Cancer Therapeutics15. Introduction to Metabolic Targets and Autophagy16. Glucose Metabolism – Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)17. Nucleic Acid Metabolism – Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)18. Amino Acid Metabolism – Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism – Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)III. Miscellaneous Cancer Therapeutic Approaches21. Targeting DNA Repair Pathways – O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair22. Cell Cycle Inhibition – Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint23. Topoisomerase-Induced DNA Damage and Therapeutic Potential24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors26. Innovative Therapeutic Approaches